Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lumateperone for Late-Life Depression
Sponsor: Eric Lenze
Summary
The purpose of this research study is to examine how well a medication called lumateperone (Caplyta) works to relieve depression in older adults with treatment-resistant depression. Lumateperone (Caplyta) is approved by the U.S. Food and Drug Administration to treat Major Depressive Disorder in adults who are also taking another antidepressant medication. This study will compare lumateperone (Caplyta) to placebo (a sugar pill without medication).
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-06
Completion Date
2028-06
Last Updated
2026-07-30
Healthy Volunteers
No
Conditions
Interventions
Lumateperone
Participants will be randomized to take either lumateperone or placebo along with their existing antidepressant for 10 weeks. Dose will range from 10.5mg-42mg over the course of the study.
Placebo
Participants will be randomized to take either lumateperone or placebo along with their existing antidepressant for 10 weeks. Dose will range from 10.5mg-42mg over the course of the study.
Locations (2)
University of Arizona
Tucson, Arizona, United States
Washington University School of Medicine
St Louis, Missouri, United States